Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$-0.53
EPS est.
$-0.48
EPS surprise
-9.50%
1-day move
-1.27%
Edgewise Therapeutics reported a loss per share that was worse than expected, leading to a slight decline in stock price by 1.27%. The lack of revenue data and management commentary leaves uncertainty about the company's performance and future outlook. Investors may be cautious as they await more information.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.53 | N/A | -9.50% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.
Edgewise Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for serious diseases. With a market cap of $5 billion, it operates in the health care sector, which is increasingly important as demand for new treatments continues to grow.
Last quarter
In Q1 2026, Edgewise reported an EPS of -$0.46, which was better than the expected -$0.50, marking an 8.18% surprise. However, the stock fell 3.81% the following day, indicating mixed market reactions.
EPS beat streak
0Q
EPS beat rate
63%
Avg EPS surprise
+1.49%
Avg 1-day reaction
-2.11%
Investors are cautiously optimistic about Edgewise's upcoming earnings report, given its history of beating EPS estimates. However, the lack of revenue guidance adds uncertainty to expectations.
Bull case
If Edgewise can continue its trend of beating EPS estimates, it may signal strong operational efficiency and investor confidence, potentially driving the stock higher.
Bear case
Conversely, if the company fails to meet expectations or provides no clear guidance, it could lead to further declines in stock price, especially given the recent negative reactions to earnings.
The print will turn on these.
Q1
What will the EPS be for Q2-2026?
The EPS figure will be critical in determining if the company can maintain its trend of beating expectations and instill confidence in investors.
Q2
Will there be any guidance on revenue growth?
Clear guidance on revenue growth is essential for understanding the company's future prospects and its ability to capitalize on market opportunities.
—
Est. EPS
$0.67
Est. Rev
$396M
Impl. Move
±10.3%
Why consensus could be wrong
The Street may be underestimating the potential for Edgewise to exceed EPS expectations based on its historical performance.
Supporting evidence
The company has a 75% EPS beat rate over the last eight quarters, indicating a strong track record.
Options pricing suggests a larger move than historical averages, which could indicate higher expectations from traders.
Key risk
If the EPS comes in better than -$0.40, it could challenge the current cautious sentiment.
Pre-commit to what would confirm each case.
The market is debating whether Edgewise can sustain its recent performance and provide clear guidance on future growth.
Bull confirmed if
An EPS of -$0.40 or better would confirm the bull case and indicate strong operational performance.
Bear confirmed if
An EPS worse than -$0.50 would confirm the bear case and raise concerns about the company's financial health.
What the market is pricing for the move.
Implied Move
±4.5%
Historical Avg
±2.4%
The options market is pricing in a significant move of 4.5%, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±4.5% while EWTX has averaged ±2.4% over the last 8 prints — setup is pricing rich.
ATM IV
0.9%
30d HV
67.4%
Smart-money positioning from the most recent 13F filings.
Institutional
111.68%
of float
Insider
0.49%
of float
Holders
321
institutions
Top Holders· as of Jun 2026
Orbimed Advisors LLC.
15,518,492 sh · $614.1M
14.29%
Flat
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Edgewise beats expectations, history suggests the stock could see an average one-day move of +2.89%, confirming bullish sentiment.
In line / cautious
If results are in line but cautious commentary is provided, the stock may experience muted movement as investors reassess their outlook.
Miss
If the company misses expectations, history suggests an average one-day move of -1.99%, likely leading to a negative market reaction.
The lines on the call that would change the story.
Paradigm Biocapital Advisors LP
10,215,455 sh · $404.2M
9.41%
38.7%
RA Capital Management, L.P.
8,392,730 sh · $332.1M
7.73%
-19.5%
Blackrock Inc.
6,606,336 sh · $261.4M
6.08%
2.1%
Jupiter Topco LLC
6,075,331 sh · $240.4M
5.59%
100.0%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.